IDENTIFICATION OF POTENTIAL INHIBITORS FOR LOWERING CHOLESTEROL LEVEL BY INHIBITING PCSK9

VIKAS REDDY V; MOURYA REDDY CH; Rathi Suganya p

doi:10.22159/ajpcr.2016.v9i6.14272

Authors

VIKAS REDDY V
MOURYA REDDY CH
Rathi Suganya p SRM University

DOI:

https://doi.org/10.22159/ajpcr.2016.v9i6.14272

Abstract

ABSTRACT

Objective: PCSK9 has medical significance in lowering cholesterol levels. Inhibitors target and inactivate PCSK9 in the liver. Knocking out PCSK9 (proprotein convertase subtilisin kexin 9) reduces the amount of harmful LDL cholesterol circulating in the bloodstream. There are two known inhibitors for treating the cardiovascular disease Arilocumabâ€ and Evalocumabâ€. However there are many side-effects. The current study is to identify natural and synthetic inhibitor using the pharmacophoric feature of the known inhibitor and validating the short listed candidates using Molecular dynamics and ADMET properties.

Methods: Known inhibitors for the PCSK9 Protein were taken from the BINDING DATABASE. Molecular docking was performed for the known inhibitors with the PCSK9 protein. After docking the best inhibitor was selected and the docking result was then imported to find the pharmacophoric features.

Results: The pharmacophore model was generated with 3 features containingÂ 1 hydrogen bond acceptor(A),1 Hydrogen bond donor(B) and 1 Aromatic ring. The constructed e-pharmacophore model was screened with more than 20000 natural compounds. 5 compounds were short listed. Among them ZINC85625485 hasÂ glideÂ scoreÂ ofÂ -13.03Â kcal/molÂ withÂ glideÂ energyÂ wasÂ -57.62 kcal/mol and ZINC85625406 has glide score of -8.1kcal/mol with glide energy was -39.33kcal/mol were taken as the best Hits.

Conclusion: PCSK9 is known to be a therapeutic agent as it controls the plasma LDL cholesterol levels by posttranslational regulation of the LDL receptor. Therefore, up-regulation of PCSk9 can lead to elevated cholesterol level in such case inhibition of PCSK9 will be a effective remedy. In this study already known inhibitors were taken and pharmacophore feature was generated. Zinc database was screened to find out novel compounds with similar pharmacophore features that can act as potentially active compound against PCSK9. ZINC85625485 and ZINC85625406 were short listed as lead compounds with Molecular dynamics simulation and checking the ADMET properties.

Â

Keywords: PCSK9, Docking, ADMET, Molecular Dynamics.

Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

Downloads

Download data is not yet available.

Author Biography

Rathi Suganya p, SRM University

Department of genetic engineering

References

Chorba JS, Shokat KM. The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis. J Biol Chem 2014;289(42):29030-43.

Peterson AS, Fong LG, Young SG. PCSK9 function and physiology. J Lipid Res 2008;49(7):1595-9.

Lagace TA. PCSK9 and LDLR degradation: Regulatory mechanisms in circulation and in cells. Curr Opin Lipidol 2014;25(5):387-93.

Zhang DW, Garuti R, Tang WJ, Cohen JC, Hobbs HH. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A 2008;105(35):13045-50.

McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem 2007;282(29):20799-803.

Sharma R, Chetia DI. Docking studies on quinine analogs for plasmepsin-II of malaria parasite using bioinformatics tools. Int J Pharm Pharm Sci 2013;5(3):681-5.

Nair PP, Chandrashekarappa KK, Masagalli JN, Nagaraja P, Mahadevan KM. Toxicity and molecular docking studies of tetrahydroquinolines against microbial, cancer, retinoic acid receptor, inflammatory, cholesterol ester transferases and parasitic protein receptorstoxicity and molecular docking studies of tetrahydroquinolines AG. Int J Pharm Pharm Sci 2014;7(2):448-59.

Ganugapati J, Swarna S. Molecular docking studies of antidiabetic activity of cinnamon compounds. Asian J Pharm Clin Res 2014;7(3):31-4.

SchrÃ¶dinger LLC. LigPrep Version 2.5. New York, NY: SchrÃ¶dinger LLC; 2011.

Jorgensen WL, Tirado-Rives J. The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and Crambin. J Am Chem Soc 1988;110:1657-66.

Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 2001;105(28):6474-87.

Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 2013;27(3):221-34.

Halgren TA. Identifying and characterizing binding sites and assessing druggability. J Chem Inf Model 2009;49(2):377-89.

Halgren T. New method for fast and accurate binding-site identification and analysis. Chem Biol Drug Des 2007;69(2):146-8.

Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006;49(21):6177-96.

Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, et al. Glide: A new approach for rapid, accurate docking and scoring 2. Enrichment factors in database screening. J Med Chem 2004;47(7):1750-9.

Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: A new approach for rapid, accurate docking and scoring 1. Method and assessment of docking accuracy. J Med Chem 2004;47(7):1739-49.

SchrÃ¶dinger LLC. Small-Molecule Drug Discovery Suite 2016-2: QikProp, Version 4.8. New York, NY: SchrÃ¶dinger LLC; 2016.